The sprawling 134-year-old health conglomerate eked out 0.6% sales growth in 2019 thanks to the strong performance of its pharmaceutical business, and particularly its immunology and oncology drugs. J&J’s consumer business—with a portfolio that includes Neutrogena, Tylenol, and Listerine—was boosted by the acquisition of Zarbee’s, a purveyor of naturally based over-the-counter remedies. The company continued its push into the robotic surgery market in an effort to revive its struggling medical device business. J&J is also mired in litigation surrounding its opioid and baby powder products. No surprise, the company has been impacted by COVID-19 in various ways; while its pharma division is racing to develop a vaccine, sales of products like artificial knees and hips are down due to the cancellation of elective surgeries during the pandemic.